Neurotrophins: From enthusiastic expectations through sobering experiences to rational therapeutic approaches

Nature Neuroscience

Volumn 5, Issue , 2002, Pages 1046-1050

  Thoenen, Hans ^a   Sendtner, Michael ^b  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BLOOD BRAIN BARRIER; CATALYSIS; CHOLINERGIC NERVE CELL; MULTIGENE FAMILY; NERVE DEGENERATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STRUCTURE ANALYSIS;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; NERVE GROWTH FACTORS; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT FAILURE;

EID: 0036829006     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn938     Document Type: Review

References (55)

1. Levi-Montalcini, R. The nerve growth factor: Thirty-five years later. EMBO J. 6, 1145-1154 (1987).
2. Barde, Y.-A. The nerve growth factor family. Prog. Growth Factor Res. 2, 237-348 (1990).
3. Bibel, M. & Barde, Y.-A. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14, 2919-2937 (2000).
4. Kaplan, D. R. & Miller, F. D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381-391 (2000).
5. Sofroniew, M. V., Howe, C. L. & Mobley, W. C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24, 1217-1281 (2001).
6. Hempstead, B. L. The many faces of p75 (NTR). Curr. Opin. Neurobiol. 12, 260-267 (2002).
7. Donovan, M. J. et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127, 4531-4540 (2000).
8. Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H. & Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: Implications for inflammatory and degenerative neurological diseases. Ann. Neurol. (in press).
9. Hefti, F. & Weiner, W. J. Nerve growth factor and Alzheimer's disease. Ann. Neurol. 20, 275-281 (1986).
10. Fisher, W. et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329, 65-68 (1987).
11. Lindsay, R. M., Wiegand, S. J., Altar, C. A. & DiStefano, P. S. Neurotrophic factors: from molecule to man. Trends Neurosci. 17, 182-190 (1994).
12. Sendtner, M., Holtmann, B. & Hughes, R. A. The response ofmotoneurons to neurotrophins. Neurochem. Res. 21, 831-841 (1996).
13. Sendtner, M. et al. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 358, 502-504 (1992).
14. Mitsumoto, H. et al. Arrests of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 265, 1107-1110 (1994).
15. Dittrich, F. et al. Pharmacokinetics of intrathecally apllied BDNF and effects on spinal motoneurons. Exp. Neurol. 141, 225-239 (1996).
16. Knusel, B. et al. Ligand-induced down-regulation of trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. Neuroscience 78, 851-862 (1997).
17. Thoenen, H. in Axonal Regeneration in the Central Nervous System (eds. Ingoglia, N.A. & Murray, M.) 675-697 (Marcel Dekker, New York and Basel, 2000).
18. McAllister, A. K., Katz, L. C. & Lo, D. C. Neurotrophins and synaptic plasticity. Annu. Rev. Neurosci. 22, 295-318 (1999).
19. Zhang, L. I. & Poo, M.-M. Electrical activity and development of neural circuits. Nat. Neurosci. 4 (Suppl), 1207-1214 (2001).
20. Berardi, N., Pizzorusso, T. & Maffei, L. Critical periods during sensory development. Curr. Opin. Neurobiol. 10, 138-145 (2000).
21. Binder, D. K., Croll, S. D., Gall, C. M. & Scharfman, H. E. BDNF and epilepsy: Too much of a good thing? Trends Neurosci. 24, 47-53 (2001).
22. Lowenstein, P. R. & Enquist, L. W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
23. Gravel, C., Gotz, R., Lorrain, A. & Sendtner, M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat. Med. 3, 765-770 (1997).
24. Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000).
25. Rossi, F. M. V. & Blau, H. M. Recent advances in inducible gene expression systems. Curr. Opin. Biotechnol. 9, 451-456 (1998).
26. Mansuy, I. M. & Bujard, H. Tetracycline-regulated gene expression in the brain. Curr. Opin. Neurobiol. 10, 593-596 (2000).
27. McKay, R. Stem cells - Hype and hope. Nature 406, 361-364 (2000).
28. Huang, Z. J. et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 98, 739-755 (1999).
29. Cotman, C. W. & Berchtold, N. C. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25, 295-301 (2002).
30. Carro, E., Nuñez, A., Busiguina, S. & Torres-Aleman, I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20, 2926-2933 (2000).
31. Carro, E., Trejo, J. L., Busiguina, S. & Torres-Aleman, I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci. 21, 5678-5684 (2001).
32. Baekelandt, V., De Strooper, B., Nuttin, B. & Debyser, Z. Gene therapeutic strategies for neurodegenerative diseases. Curr. Opin. Mol. Ther. 2, 540-554 (2000).
33. Vigna, E. et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Therapy 5, 252-261 (2002).
34. Cheng, L., Saphieha, P., Kittlerova, P., Hauswirth, W. W. & Di Polo, A. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J. Neurosci. 22, 3977-3986 (2002).
35. Lee, F. S., Rajagopal, R. & Chao, M. V. Distinctive features of Trk neurotrophins receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev. 13, 11-17 (2002).
36. Hefti, F. Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. 37, 239-267 (1997).
37. Swain, C., Harper, S., Polack, S., Smith, R. & Hefti, F. in Handbook of Experimental Pharmacology (ed. Hefti, F.) 281-309 (Springer Verlag, Heidelberg/Berlin, 1999).
38. Venters, H. D., Dantzer, R. & Kelley, K. W. A new concept in neurodegeneration: TNF-alpha is a silencer of survival signals. Trends Neurosci. 23, 175-180 (2000).
39. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin. Neuropharmacol. 18, 515-532 (1995).
40. Miller, R. G. et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39, 256-260 (1996).
41. ALS CNTF Treatment Study group (ACTS). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 46, 1244-1249 (1996).
42. Aebischer, P. et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2, 696-699 (1996).
43. Penn, R. D., Kroin, J. S., York, M. M. & Cedarbaum, J. M. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 40, 94-99 (1997).
44. Bachoud-Levi, A. C. et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum. Gene Ther. 11, 1723-1729 (2000).
45. Ericsdotter Jönhagen, M. et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia Geriatr. Cogn. Disord. 9, 246-257 (1998).
46. Apfel, S. C. et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51, 695-702 (1998).
47. Apfel, S. C. et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284, 2215-2221 (2000).
48. McArthur, J. C. et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54, 1080-1088 (2000).
49. Schifitto, G. et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57, 1313-1316 (2001).
50. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52, 1427-1433 (1999).
51. Ochs, G. et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 201-206 (2000).
52. Wellmer, A., Misra, V. P., Sharief, M. K., Kopelman, P. G. & Anand, P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J. Peripher. Nerv. Syst. 6, 204-210 (2001).
53. Chaudhry, V. et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 23, 189-192 (2000).
54. Lai, E. C. et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49, 1621-1630 (1997).
55. Borasio, G. D. et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583-586 (1998).